Mod­er­na tries its hand at CRISPR through a new de­vel­op­ment pact with Metageno­mi

Mod­er­na has al­ways been think­ing about how mR­NA could trans­form the gene edit­ing space, ac­cord­ing to Er­ic Huang. In fact, they looked at it about a decade ago — but at the time, they were still a small, pre­clin­i­cal biotech, and tech­nol­o­gy like that would take some time to ma­ture.

Then the pan­dem­ic hit, and the rest is his­to­ry.

“Now, I think it’s the right time,” said Huang, CSO of Mod­er­na’s ge­nomics busi­ness.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER